XGN · NASDAQ
Exagen Inc.
$8.56 +0.24 (+2.88%)
Company overview
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Exchange
- NASDAQ
- Market cap
- $207M
- Employees
- 209
- Headquarters
- Vista, CA
- Website
- exagen.com
- CEO
- John Aballi
- Listed
- September 19, 2019
- P/E
- -9.48
- Dividend yield
- 0.00%
Company financials
- Revenue
- $68.4M
- Gross profit
- $39.9M
- Operating income
- -$14.1M
- EBITDA
- -$15.9M
- Net income
- -$20.2M
- EPS
- -$0.90
- Total assets
- $52M
- Total debt
- $4.9M
- Gross margin
- 58.32%
- Net margin
- -29.49%
- Earnings yield
- -10.55%
No geographic segmentation.
Showing FY 2025
XGN
1D
NASDAQ
O7.80H8.49L7.79C8.32+0.54 (+6.94%)Vol102.66K